Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry
: Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, Beitner-Johnson D, Benistan K, Cabrera G, Charrow J, Kantola I, Linhart A, Nicholls K, Niemann M, Scott CR, Sims K, Waldek S, Warnock DG, Strotmann J
Publisher: NATURE PUBLISHING GROUP
: 2013
: Genetics in Medicine
: GENETICS IN MEDICINE
: GENET MED
: 12
: 15
: 12
: 958
: 965
: 8
: 1098-3600
DOI: https://doi.org/10.1038/gim.2013.53
Conclusion: Agalsidase-beta treatment for >= 2 years may improve or stabilize left-ventricular mass in men with Fabry disease. Further investigations may determine whether early intervention and stabilization of LVM are correlated with clinical outcomes.